World Parkinson Congress 2025

The World Parkinson Congress (WPC) is the premier triennial international gathering bringing together the entire [Parkinson's disease](/diseases/parkinsons-disease) community — including researchers, clinicians, people living with Parkinson's, care partners, and advocacy organizations. The 2025 Congress continues this tradition of inclusive, patient-centered scientific exchange that distinguishes WPC from other neuroscience meetings[@wpc].

Overview

The World Parkinson Congress (WPC) is the premier triennial international gathering bringing together the entire [Parkinson's disease](/diseases/parkinsons-disease) community — including researchers, clinicians, people living with Parkinson's, care partners, and advocacy organizations. The 2025 Congress continues this tradition of inclusive, patient-centered scientific exchange that distinguishes WPC from other neuroscience meetings[@wpc].

Overview

The World Parkinson Congress is unique among neurodegenerative disease conferences in its fundamental commitment to including people with Parkinson's as active participants, presenters, and leaders. This patient-inclusive approach reflects the growing recognition that the lived experience of Parkinson's provides essential insights that complement traditional clinical and basic science perspectives["@wpc"][@bloem2024].

The 2025 Congress serves as a critical platform for:

• Translating basic science discoveries into clinical applications
• Showcasing results from pivotal clinical trials in Parkinson's disease
• Facilitating collaboration between academic researchers, industry, and patient advocates
• Discussing emerging therapeutic approaches and disease-modifying strategies
• Addressing the holistic needs of people living with Parkinson's and their families

2025 Congress Details

| Item | Details |
|------|---------|
| Dates | September 2025 |
| Location | Barcelona, Spain — International Convention Centre |
| Organizer | World Parkinson Congress Foundation |
| Website | [www.wpc2025.org](https://www.wpc2025.org) |
| Expected Attendees | 4,000+ from 60+ countries |

Conference Themes

Alpha-Synuclein Biology and Pathology

The [alpha-synuclein](/proteins/alpha-synuclein) protein remains the central focus of Parkinson's research, with the 2025 Congress featuring the latest advances in understanding its biology and role in disease pathogenesis. Key topics include:

Aggregation Mechanisms

• Molecular triggers of alpha-synuclein misfolding and aggregation
• Role of genetic factors ([SNCA](/genes/snca) mutations, duplications) in aggregation propensity
• Impact of post-translational modifications (phosphorylation, ubiquitination) on aggregation
• Cell-to-cell transmission of pathological alpha-synuclein

• Immunotherapy approaches: active and passive vaccination strategies
• Small molecule aggregation inhibitors
• Gene therapy approaches targeting SNCA expression
• Calcium channel modulators affecting alpha-synuclein dynamics[@schapira2019]

Parkinson's Genetics and Precision Medicine

Genetic discoveries have transformed our understanding of Parkinson's disease, and the Congress will feature comprehensive coverage of:

Major Parkinson's Genes

• [LRRK2](/genes/lrrk2): The most common genetic cause of sporadic Parkinson's, with kinase inhibitor trials advancing
• [GBA](/genes/gba): Glucocerebrosidase mutations conferring significant Parkinson's risk, with enzyme replacement approaches in development
• [SNCA](/genes/snca): Alpha-synuclein gene mutations establishing the centrality of protein aggregation
• [PARKIN](/genes/parkin): Autosomal recessive young-onset Parkinson's
• [PINK1](/genes/pink1): Mitochondrial quality control in early-onset Parkinson's
• [DJ-1](/genes/dj1): Oxidative stress response
• [ATP13A2](/genes/atp13a2): Lysosomal function in Kufor-Rakeh syndrome

• Genotype-stratified clinical trial designs
• Gene-specific therapeutic development
• Polygenic risk scores for patient stratification
• Population-specific genetic architecture[@axelsen2024]

Disease-Modifying Therapies

The development of therapies that can slow or halt Parkinson's progression represents the field's highest priority:

Alpha-Synuclein Immunotherapy

• Cinpanemab (BIIB054): Anti-alpha-synuclein antibody showing disease-modifying potential
• Prasinezumab (RO7046015/PRX002): Promising signals in early Parkinson's
• Lu AF87908: Anti-alpha-synuclein antibody in early clinical development
• Active vaccination strategies targeting pathological alpha-synuclein species[@foltin2023]

• BIIB122 (DNL151): LRRK2 kinase inhibitor completing pivotal trials
• DNL151: Demonstrating target engagement and safety in Phase 1/2
• Kinase inhibitor approaches for LRRK2-associated Parkinson's[@mikhailova2024]

• Inosine supplementation to elevate urate (neuroprotective antioxidant)
• GLP-1 receptor agonists (exenatide, liraglutide) showing promise
• CoQ10 and mitochondrial protectants
• AMPA receptor modulators

Biomarkers and Diagnostics

Early and accurate diagnosis remains critical for implementing disease-modifying therapies:

Fluid Biomarkers

• Alpha-synuclein seed amplification assays (RT-QuIC, PMCA)
• Neurofilament light chain (NfL) for disease progression monitoring
• p-tau181 and p-tau217: Emerging Alzheimer's markers with cross-disease relevance
• Metabolomic and proteomic signatures

• Dopamine transporter (DAT) SPECT imaging
• Tau PET imaging in atypical parkinsonism
• Novel alpha-synuclein PET tracers (in development)
• Neuromelanin MRI

• Wearable sensors for movement analysis
• Voice and speech analysis
• Gait pattern analysis
• Continuous monitoring approaches[@park2024]

Non-Motor Symptoms

Recognition of non-motor symptoms as major determinants of quality of life has grown substantially:

Neuropsychiatric Features

• Depression and anxiety: Prevalence, pathophysiology, treatment
• Apathy: Distinct from depression, specific therapeutic approaches
• Psychosis: Visual hallucinations, management strategies
• Impulse control disorders: Dopamine agonist-related behaviors[@bhatia2023]

• REM sleep behavior disorder (RBD): Prodromal marker and correlate
• Insomnia and fragmentation
• [Restless legs syndrome](/diseases/restless-legs-syndrome)

• [Orthostatic hypotension](/diseases/orthostatic-hypotension)
• Gastrointestinal dysfunction (constipation, nausea)
• Urinary symptoms
• Sexual dysfunction

• Mild cognitive impairment in Parkinson's
• Parkinson's disease dementia
• Relationship to cholinergic degeneration[@aarsland2021]

Motor Complications

Advanced Parkinson's presents significant therapeutic challenges:

Motor Fluctuations

• Wearing-off phenomena
• On-off phenomena
• Delayed-on and no-on
• Management strategies

• Levodopa-induced dyskinesias (LID)
• Pathophysiology
• Surgical interventions (DBS)
• Pharmacological management

• Freezing of gait (FOG)
• Falls and fall prevention
• Postural instability[@poston2023]

Surgical and Device-Based Therapies

Deep Brain Stimulation

• STN vs. GPi targets: Comparative effectiveness
• Adaptive DBS (closed-loop systems)
• MRI-guided focused ultrasound
• Post-operative programming optimization[@weinberger2024]

• Levodopa-carbidopa intestinal gel (LCIG)
• Apomorphine infusion
• Continuous subcutaneous apomorphine

Emerging Therapies

Cell Replacement Therapy

• Embryonic stem cell-derived dopamine neurons
• Induced pluripotent stem cell (iPSC) approaches
• Patient-specific cell therapies
• Current clinical trial status[@stoker2024]

• AAV-based delivery (AADC deficiency, GAD, neurotrophic factors)
• CRISPR-based approaches
• RNA interference for SNCA reduction

• GLP-1 receptor agonists (exenatide, liraglutide)
• Ambroxol (GCase enhancer)
• Lithium (neuroprotective)
• Statins

Basic Science Advances

Neuroinflammation

• Microglial activation in Parkinson's pathogenesis
• Complement system involvement
• T cell involvement in neurodegeneration
• Anti-inflammatory therapeutic approaches[@caceres2024]

• PINK1/Parkin mitophagy pathway
• Complex I deficiency
• Mitochondrial DNA mutations
• Metabolic therapies

• Alpha-synuclein at the synapse
• Synucleinopathies and synaptic protein networks
• Vesicle trafficking impairment

• Adult neurogenesis in the subventricular zone
• Exercise-induced neuroplasticity
• Rehabilitation approaches

Clinical Trial Design

The Congress addresses critical issues in Parkinson's clinical trials:

Outcome Measures

• MDS-UPDRS: Gold standard for motor symptoms
• Patient-reported outcomes
• Digital outcome measures
• Composite endpoints

• Early vs. advanced Parkinson's
• Genetically-defined subpopulations
• Prodromal cohorts
• Enrichment strategies using biomarkers

• Platform trials
• Adaptive designs

Patient-Centered Research

The unique inclusion of patients at WPC fosters:

Patient-Reported Outcomes

• Quality of life measures
• Daily functioning assessments
• Treatment satisfaction
• Unmet needs identification

• Community-based participatory research
• Patient advocacy organization initiatives
• Fundraising and awareness campaigns

• Self-management strategies
• Care partner perspectives
• Support groups and community resources

Conference Structure

Session Types

• Keynote Lectures: Major addresses by field leaders
• Plenary Sessions: Cross-cutting scientific presentations
• Oral Abstract Sessions: Selected research presentations
• Poster Sessions: Interactive research displays
• Workshop Sessions: Focused educational content
• Patient-Focused Sessions: Unique to WPC
• Networking Events: Collaboration and community building

Daily Program Highlights

Research Days

• Basic science symposia
• Clinical trial results presentations
• Biomarker and diagnostic sessions

• Diagnosis and management updates
• Therapeutic strategies
• Non-motor symptoms workshops

• Patient education sessions
• Interactive Q&A with researchers
• Advocacy and community events

Venue: Barcelona, Spain

Barcelona offers world-class facilities for the Congress:

International Convention Centre (CCIB)

• Modern conference facilities
• Accessible location near port
• State-of-the-art audiovisual equipment
• Multiple simultaneous session rooms
• Exhibition space for industry partners

Getting There

From Barcelona-El Prat Airport

• Metro L9 Sud to Ciutadella | Vila Olímpica station
• Taxi: 20-30 minutes
• Shuttle services available

• Metro L3 to Ciutadella | Vila Olímpica
• Taxi: 10-15 minutes

About Barcelona

• Home to Hospital Clínic and IDIBAPS (major Parkinson's research center)
• Parkinson's disease research excellence at University of Barcelona
• Accessible city with excellent public transportation
• Mediterranean climate
• Rich cultural attractions

Historical Context

The World Parkinson Congress has evolved significantly:

| Year | Location | Key Themes |
|------|----------|------------|
| 2010 | Glasgow | First patient-inclusive format |
| 2013 | Montreal | Alpha-synuclein biology emphasis |
| 2016 | Kyoto | Genetics and precision medicine |
| 2019 | Shanghai | Disease-modifying therapies |
| 2022 | Barcelona (virtual) | COVID-19 and Parkinson's |
| 2025 | Barcelona | Disease modification and precision medicine |

Related Conferences and Organizations

Major Parkinson's Conferences

• [AD/PD 2026](/events/adpd-2026) — Alzheimer's & Parkinson's Diseases Conference
• [MDS 2026](/events/mds-2026) — Movement Disorder Society Meeting
• [International Congress on Parkinson's Disease](/events/international-congress-parkinsons-disease)
• [AAIC](/events/aaic-2026) — Alzheimer's Association International Conference (PD sessions)

Parkinson's Organizations

• Parkinson's Foundation
• Michael J. Fox Foundation
• European Parkinson's Disease Association
• Parkinson's UK

Related Conditions

• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Disease Research](/diseases/parkinsons-disease-research)
• [Parkinson's Disease Genetics](/diseases/parkinsons-disease-genetics)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [LRRK2](/genes/lrrk2)
• [GBA](/genes/gba)
• [Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)
• [LRRK2 Inhibitor Therapy](/therapeutics/lrrk2-inhibitor-therapy)
• [Clinical Trials in Parkinson's Disease](/clinical-trials)
• [Biomarkers in Parkinson's Disease](/biomarkers)
• [Parkinson's Disease Treatment](/therapeutics/parkinson-disease-treatment)
• [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
• [Conference Index](/events/conference-index)

External Links

• [World Parkinson Congress](https://www.worldparkinsoncongress.org)
• [WPC 2025](https://www.wpc2025.org)
• [Parkinson's Foundation](https://www.parkinson.org)
• [Michael J. Fox Foundation](https://www.michaeljfox.org)

References